StockData
Zimmer Biomet Holdings, Inc. logo

Zimmer Biomet Holdings, Inc. (ZBH) stock

ZBHNYSEOrthopedic, Prosthetic & Surgical Appliances & SuppliesFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026Score 17/3024% below fair value
$94.52−2.95 (-3.03%)

Close on Oct 30, 2026Market cap $18.03BP/E 23.0Yield 1.02%

Earnings

Zimmer Biomet's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.

Next report
Nov 4, 2026
Q3 FY2026 · estimated, before the open
Revenue, Q2 FY2026
$2.18B
+4.8% on a year earlier
adjusted diluted earnings per share, Q2 FY2026
$2.07
$2.07 a year earlier
Latest guidance
Raised
Aug 5, 2026 · 5 items

Quarterly results

Revenue and earnings per share from each of Zimmer Biomet's earnings releases, newest first

QuarterReportedRevenueYoYEPSAdj. EPSSource
Q3 FY2026ended Sep 30, 2026Nov 4, 2026Expected–––––
Q2 FY2026ended Jun 30, 2026Aug 5, 2026before the open$2.18B+4.8%$1.03$2.07Release
Q1 FY2026ended Mar 31, 2026Apr 28, 2026before the open$2.09B+9.3%$1.22$2.09Release
Q4 FY2025ended Dec 31, 2025Feb 10, 2026before the open$2.24B+10.9%$0.70$2.42Release
Q3 FY2025ended Sep 30, 2025Nov 5, 2025before the open$2.00B+9.7%$1.16$1.90Release
Q2 FY2025ended Jun 30, 2025Aug 7, 2025before the open$2.08B+7.0%$0.77$2.07Release
Q1 FY2025ended Mar 31, 2025May 5, 2025before the open$1.91B+1.1%$0.91$1.81Release
Q4 FY2024ended Dec 31, 2024Feb 6, 2025before the open$2.02B+4.3%$1.20$2.31Release
Q3 FY2024ended Sep 30, 2024Oct 30, 2024before the open$1.82B+4.0%$1.23$1.74Release
Q2 FY2024ended Jun 30, 2024Aug 7, 2024before the open$1.94B+3.9%$1.18$2.01Release
Q1 FY2024ended Mar 31, 2024May 2, 2024before the open$1.89B+3.2%$0.84$1.94Release
Q4 FY2023ended Dec 31, 2023Feb 8, 2024before the open$1.94B+6.3%$2.01$2.20Release

Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.

Current guidance

Zimmer Biomet's latest outlook for periods it has not reported yet, compared with what it said before

MetricPeriodGuidanceBeforeChangeGiven
Constant Currency Revenue Changenon-GAAPFY2026+3.4% – +4.4%+2% – +4%RaisedAug 5, 2026
Reported Revenue ChangeGAAPFY2026+3.9% – +4.9%+2.5% – +4.5%RaisedAug 5, 2026
Adjusted Diluted EPSnon-GAAPFY2026$8.47 – $8.59$8.40 – $8.55RaisedAug 5, 2026
Foreign Currency Exchange ImpactFY20260.5%0.5%ReaffirmedAug 5, 2026

Guidance vs results

The last range Zimmer Biomet gave before each report, against the figure it then reported. Full years add up the four quarters.

PeriodMetricGuidanceActualResult
FY2025Adjusted Diluted EPS$8.10 – $8.30$8.20Σ4QWithin range
FY2025Revenue growth+6.7% – +7.7%+7.2%Σ4QWithin range

Guidance history

Every forecast Zimmer Biomet put in an earnings release, newest first

GivenMetricPeriodGuidanceChange
Aug 5, 2026Adjusted Diluted EPSFY2026$8.47 – $8.59Raised
Aug 5, 2026Foreign Currency Exchange ImpactFY20260.5%Reaffirmed
Aug 5, 2026Reported Revenue ChangeFY2026+3.9% – +4.9%Raised
Aug 5, 2026Constant Currency Revenue ChangeFY2026+3.4% – +4.4%Raised
Aug 5, 2026Organic Constant Currency Revenue ChangeFY2026+2.25% – +3.25%Lowered
Apr 28, 2026Adjusted Diluted EPSFY2026$8.40 – $8.55Raised
Apr 28, 20262026 Reported Revenue ChangeFY2026+2.5% – +4.5%Reaffirmed
Apr 28, 20262026 Constant Currency Revenue ChangeFY2026+2% – +4%Raised
Feb 10, 2026Adjusted Diluted EPSFY2026$8.30 – $8.45New
Feb 10, 2026Foreign Currency Exchange ImpactFY20260.5%New
Feb 10, 2026Reported Revenue ChangeFY2026+2.5% – +4.5%New
Feb 10, 2026Constant Currency Revenue ChangeFY2026+2% – +4%New
Feb 10, 2026Organic Constant Currency Revenue ChangeFY2026+1% – +3%Lowered
Nov 5, 2025Adjusted Diluted EPSFY2025$8.10 – $8.30Reaffirmed
Nov 5, 2025Constant Currency Revenue ChangeFY2025+6.2% – +6.7%New
Nov 5, 2025Reported Revenue ChangeFY2025+6.7% – +7.7%Reaffirmed
Nov 5, 2025Organic Constant Currency Revenue ChangeFY2025+3.5% – +4%Lowered
Aug 7, 2025Adjusted Diluted EPSFY2025$8.10 – $8.30New
Aug 7, 2025Foreign Currency Exchange ImpactFY20250.5%New
Aug 7, 20252025 Reported Revenue ChangeFY2025+6.7% – +7.7%New

Read from the company's earnings releases; each figure links to its sentence on hover. “Raised” and “Lowered” compare with the previous range for the same metric and period.

Press releases

Releases Zimmer Biomet filed with the SEC as exhibits to Form 8-K or 6-K

  1. Zimmer Biomet Announces Americas Leadership Promotions to Accelerate Commercial Transformation
    Update
  2. The following items of the 2025 Form 10-K are being recast as reflected in this Exhibit 99.1:
    News
  3. Second Quarter 2026 Financial Results
    Results
  4. Zimmer Biomet Increases Share Repurchase Expectations —
    Update
  5. Zimmer Biomet Announces Chief Financial Officer Transition
    Update
  6. First Quarter 2026 Financial Results
    Results
  7. Fourth Quarter and Full-Year 2025 Financial Results
    Results
  8. Third Quarter 2025 Financial Results
    Results
  9. Zimmer Biomet Completes Acquisition of Monogram Technologies
    News
  10. Second Quarter 2025 Financial Results
    Results
  11. MOVING YOU FORWARD July 14, 2025 ZBH
    Update
  12. Zimmer Biomet Announces Definitive Agreement to Acquire Monogram
    Update
  13. Zimmer Biomet Appoints Kevin Thornal as
    Update
  14. First Quarter 2025 Financial Results
    Results
  15. Zimmer Biomet Completes Acquisition of Paragon 28
    News